We have closed our ￡26m Series B follow-on financing. The round was led by new #investor Panakes Partners, joined by our existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group plc. The #investment will fund the Phase 2a #clinical #proofofconcept trial in #cysticfibrosis for our lead programme, ETD001. With first-in-class potential, ETD001 targets the ENaC #ionchannel in the airway epithelium, increasing the hydration and clearance of mucus to drive substantial improvements in #lungfunction. Funds will also support the progression of our other #preclinical programmes targeting the underlying mechanisms of mucus congestion in chronic #respiratory diseases. Alongside the financing, we are delighted to welcome Dr Rob Woodman, Partner at Panakes, to our #BoardofDirectors. Read the full press release here:?https://rb.gy/kr6wf5
Andrew Grace
1 年
Congratulations, delighted to see, real case of need, in sum brilliant progress
Tom Lazenby
1 年
Congrats Enterprise Therapeutics and all the people that made this happen!
Mark Keogh
1 年
Congratulations, John. Excellent outcome, well done to you and all the team ??????
Jonathan Savidge
1 年
Many congratulations to you all and very best of luck with the Phase II
Damian Bell
1 年
Great news Martin Gosling, Sarah Lilley & all who've worked over the years to make Enterprise Therapeutics so successful. Cheers
Emma Hodge
1 年
Congratulations
Mark Chadwick
1 年
Nice one John Ford. Many congrats to you and your team!
Mark Treherne
1 年
Congrats, John and team
Ian Richards
1 年
Congratulations John and the whole team
CEO Enterprise Tx / Chair ARMGO Tx / Chair Complement Tx
1 年So pleased - big thank you to the ETx team and board. Looking forwarding to working with Rob and the Panakes team too. Exciting times….